Patent Term Extensions and Filings for Regulatory Exclusivity Periods. RBNC will advise AMGEN when it is considering any patent term extension or supplementary protection certificates or their equivalent for the Licensed Patents, Program Patents or Joint Patents. With respect to any patent listings required for any Regulatory Exclusivity for the Products, the Parties will discuss in good faith which Licensed Patents, Joint Patents or Program Patents, if any, to list; provided, the decision as to which Patents are listed resides with RBNC.
Appears in 4 contracts
Samples: Exclusive License Agreement (Neumora Therapeutics, Inc.), Exclusive License Agreement (Neumora Therapeutics, Inc.), Exclusive License Agreement (Neumora Therapeutics, Inc.)
